BNP PARIBAS ARBITRAGE/PUT/GRIFOLS CL. A/13/1/20.12.24 Stock

Warrant

K7150

NLBNPES1OSF8

Market Closed - BME 11:30:00 2024-05-23 am EDT
4.44 EUR +1.60% Intraday chart for BNP PARIBAS ARBITRAGE/PUT/GRIFOLS CL. A/13/1/20.12.24
Current month-9.76%
1 month-11.38%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 4.44 +1.60%
24-05-22 4.37 +9.25%
24-05-21 4 +1.01%
24-05-20 3.96 +0.25%
24-05-17 3.95 +0.77%

Delayed Quote BME

Last update May 23, 2024 at 11:30 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying GRIFOLS, S.A.
IssuerLogo Issuer BNP Paribas BNP Paribas
K7150
ISINNLBNPES1OSF8
Date issued 2024-01-11
Strike 13
Maturity 2024-12-20 (211 Days)
Parity 1 : 1
Emission price 1.84
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 6.44
Lowest since issue 1.84
Delta-0.65x
Omega 1.342
Premium6.28x
Gearing2.07x
Moneyness 1.421
Difference Strike 3.85
Difference Strike %+29.62%
Spread 0.01
Spread %0.23%
Theoretical value 4.425
Implied Volatility 67.61 %
Total Loss Probability 18.48 %
Intrinsic value 3.850
Present value 0.5750
Break even 8.575 €
Theta-0.02x
Vega0.03x
Rho-0.04x

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Sector
-
More about the company

Ratings for Grifols, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Grifols, S.A.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
9.268 EUR
Average target price
16.88 EUR
Spread / Average Target
+82.12%
Consensus
  1. Stock Market
  2. Warrants
  3. K7150 Warrant